NovoLog Mix 70/30 (insulin aspart protamine 70%/insulin aspart 30%) / Novo Nordisk - LARVOL DELTA

Euglycaemic ketoacidosis after initiation of tirzepatide in a patient on chronic SGLT2 inhibition and intercurrent colitis (UKKW 2026) - "Case A 44-year-old woman with type 2 diabetes, multiple sclerosis, and coronary artery disease had been on canagliflozin since January 2021...She was discharged on 23 July 2025 on NovoMix 30 insulin (12 units AM, 10 units PM)...Next step Renal services should implement peri-procedure protocols including early suspension of SGLT2i/tirzepatide, ketone-first monitoring, and insulin–dextrose bridging. National audit is needed to quantify incidence, refine drug-hold intervals, and establish euDKA prevention as a measurable NHS safety standard."

Clinical • Cardiovascular • Chronic Kidney Disease • CNS Disorders • Coronary Artery Disease • Diabetes • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Multiple Sclerosis • Nephrology • Septic Shock • Type 2 Diabetes Mellitus

Glycaemic outcomes in hospital with IDegAsp versus BIAsp30 premixed insulins. (PubMed, Intern Med J) - "Inpatients treated with IDegAsp compared to BIAsp30 had similar hypoglycaemia incidence, but higher hyperglycaemia incidence, potentially related to less frequent twice-daily dosing. With the increasing use of IDegAsp in the community, development of hospital management guidelines for this insulin formulation is needed."

Journal • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Glycaemia in low-premixed insulin analogue type 2 diabetes patients in a real-world setting: are the CGM targets met? (PubMed, Eur J Med Res) - "Most of our type 2 diabetes patients, treated with low-premixed insulin, did not meet the recommended TBR target for older/high-risk patients while meeting the TIR and TAR targets. Nevertheless, the time spent in (total and nocturnal) hypoglycemia was short. The study indicates that the general type 2 diabetes population targets would mostly be met for TBR and %CV in our patients but not the TIR and TAR targets. CGM appears to be a useful clinical tool in these patients."

Journal • Observational data • Real-world • Real-world evidence • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Mixed insulin can improve control of prednisolone-induced hyperglycaemia. (PubMed, Intern Med J) - "Mixed insulin as a pre-breakfast or pre-breakfast and pre-lunch regimen can target the hyperglycaemic pattern induced by prednisolone and minimise overnight hypoglycaemia. However, higher doses of insulin than used in our study are likely required for optimal BGL control."

Journal • Diabetes • Hypoglycemia

"@novonordisk Can you recycle your Novomix 30 insulin pens? If so, how & where?" (@STEVEFI14205588)

Pharmacokinetic Similarity between Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 and Originator Insulin Aspart Mix 70/30 (NovoMix 30) in Indian Adults with Type 2 Diabetes: GEMELLI M Substudy. (PubMed, Indian J Endocrinol Metab) - "Other efficacy endpoints, insulin dosages, anti-insulin aspart antibody response, hypoglycemia and adverse events were similar between groups. Our results support the findings from previous studies, that SAR-Mix has a similar pharmacokinetic profile to NN-Mix and provides effective glycemic control with similar safety and immunogenicity profile in Indian adults with type 2 diabetes."

Journal • PK/PD data • Diabetes • Hypoglycemia • Metabolic Disorders • Type 2 Diabetes Mellitus

Efficacy, Safety, and Immunogenicity of Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Compared with Originator Insulin Aspart Mix 70/30 in Adults with Diabetes (GEMELLI M): A Subgroup Analysis by Prior Type of Premix Insulin. (PubMed, Diabetes Ther) - "Efficacy, safety, and immunogenicity profiles of SAR-Mix are similar to NN-Mix over 26 weeks in adults with diabetes irrespective of prior type of premix insulin."

Journal • Diabetes • Hypoglycemia • Immunology • Metabolic Disorders • Type 2 Diabetes Mellitus

Biosimilar Insulin Aspart Premix SAR341402 Mix 70/30 Versus Originator Insulin Aspart Mix 70/30 (NovoMix 30) in People with Diabetes: A 26-Week, Randomized, Open-Label Trial (GEMELLI M). (PubMed, Diabetes Ther) - "The totality of evidence indicates that SAR-Mix provides effective glycemic control with a similar safety and immunogenicity profile to NN-Mix in people with diabetes treated for 26 weeks."

Journal • Diabetes • Hypoglycemia • Infectious Disease • Metabolic Disorders • Novel Coronavirus Disease • Type 2 Diabetes Mellitus

Extreme insulin resistance during pregnancy: a therapeutic challenge. (PubMed, Endocrinol Diabetes Metab Case Rep) - "Insulin treatment was initiated immediately using Novomix 30, and the doses were progressively increased, peaking at 1420 units/day at week 34 + 4. Obesity, PCOS, T2D and high levels of leptin and IGF-1 are predictors of severe insulin resistance in pregnancy. A close collaboration between patient, obstetricians and endocrinologists is crucial for tailoring the best possible treatment for pregnant women with diabetes, beneficial for both the mother and her child."

Journal • Diabetes • Genetic Disorders • Hypoglycemia • Metabolic Disorders • Obesity • Obstetrics • Polycystic Ovary Syndrome • Type 2 Diabetes Mellitus • IGF1 • IR • LEP

Rare case of diabetic neuropathic cachexia along with diabetic amyotrophy. (PubMed, BMJ Case Rep) - "He was diagnosed with type 2 diabetes mellitus in July 2020 and was started on Metformin and Gliclazide by his in July; he was later commenced on alogliptin and empaglaflozin by diabetes specialist nurse in early August. Patient was diagnosed with diabetic neuropathic cachexia secondary to poorly controlled diabetes and was commenced on 30 units two times per day of NovoMix 30 insulin; this was adjusted to 24 units two times per day in endocrine clinic 3 months later, after gaining 10 kg in weight. Good glycaemic control is key to the management of such cases and, therefore, we recommend early referral to diabetes specialist input for consideration of insulin therapy."

Clinical • Journal • Cachexia • CNS Disorders • Depression • Diabetes • Diabetic Neuropathy • Gastrointestinal Disorder • Immunology • Metabolic Disorders • Mood Disorders • Pain • Psychiatry • Type 2 Diabetes Mellitus

Dosing accuracy of insulin aspart flexpens after transport through the pneumatic tube system (Hosp Pharm) - N=115; “...none of the 603 doses of 30 IU (0.0%; 95% CI, 0.0 to 0.6) fell outside of the range of acceptable weights... in the control group, none of the 144 doses at 10 IU (0.0%; 95% CI, 0.0 to 2.5) and none of the 153 doses at 30 IU (0.0%; 95% CI, 0.0 to 2.4).”

Clinical • Diabetes